Gain comprehensive insight into the critical aspects of ADC functional analysis & QC through 5 expert-led masterclass series, each session designed to equip researchers with actionable knowledge and practical tools, helping you overcome technical bottlenecks in ADC drug development.
Three key values this series offers:
- Comprehensive Technical Landscape: Build a systematic and comprehensive ADC bioanalytical capability framework.
- Targeted Problem Solving: Directly addresses core issues such as low internalization detection efficiency and impurity interference.
- Empowering Toolkits: Provides essential reagents and method development support throughout the ADC development lifecycle.
Jun 26th 2025-Aug 21st 2025
Online
ACROBiosystems and others
Free Registration
Agenda
Session 1: Decoding ADC functional analysis—From molecular binding to PK/ADA assessment
Speaker: Dr. Zhicheng Dong, Product Manager, ACROBiosystems
Date: 6/26/2025
Key topics:
- Molecular Binding activity detection for ADC molecules
- Key considerations for ADC pharmacokinetic (PK) analysis
- Detection and analysis of anti-drug antibodies (ADA)
Session 2: Advancing ADC internalization analysis—Technical comparison & pH-sensitive dye applications
Speaker: Dr. Zhicheng Dong, Product Manager, ACROBiosystems
Date: 7/10/2025
Key topics:
- Mechanisms of ADC internalization
- Comparison of internalization detection methods
- Practical applications of pH-sensitive reagent in internalization assays
Session 3: Triple challenge in ADC cell-based functional analysis—Internalization efficiency, cytotoxicity, and bystander effect
Speaker: Xiaojuan Shi, Cellular Products Research and Development Director, ACROBiosystems
Date: 7/24/2025
Key topics:
- Internalization analysis of ADCs
- Cytotoxicity evaluation of ADCs
- Evaluating bystander effects of ADCs
Session 4: ADC safety quality control—From rapid detection to regulatory compliance
Speaker: Dr. Yingjie Liu, Senior Product Manager, ACROBiosystems
Date: 8/7/2025
Key topics:
- Mycoplasma Rapid Detection
- Aseptic testing strategies
- Recombinant Factor C Endotoxin Detection
Session 5: Critical residual analysis in ADCs—Host cell DNA & affinity ligand residual risk management
Speaker: Dr. Yingjie Liu, Senior Product Manager, ACROBiosystems
Date: 8/21/2025
Key topics:
- Residual Host cell DNA detection
- Residual Affinity Ligands Detection
Speakers
Xiaojuan Shi, Cellular Products Research and Development Director, ACROBiosystems
Xiaojuan Shi currently serves as the Director of Cellular Products Research and Development at ACROBiosystems. With 20+ expertise in pharmaceutical industry platform and product technology research and development, she has held technical leadership roles at several renowned research institutes, CRO companies, and pharmaceutical R&D firms. She has applied and obtained for multiple technical patents and possesses extensive expertise in the biopharmaceutical field, particularly in antibody therapeutics and cell therapy.
Dr. Yingjie Liu, Senior Product Manager, ACROBiosystems
Dr. Yingjie Liu, a graduate of National Yang Ming Chiao Tung University, specializes in tumor microenvironment regulation and metabolic reprogramming. With extensive experience in quality control for cell and gene therapy, she has developed processes meeting FDA and EMA standards. Proficient in CGT, IVT, and ADC quality control, she seamlessly incorporates compliance requirements throughout the quality control process. Dr. Liu possesses a deep understanding of pharmaceutical regulations in China, the US, and Europe.
Dr. Zhicheng Dong, Product Manager, ACROBiosystems
Dr. Zhicheng Dong possesses extensive expertise in developing analytical and quality control solutions for emerging modalities, including ADCs, therapeutic antibodies, and AAV-based therapies. With extensive experience across the full lifecycle of ADC development—from target validation and potency analysis in early R&D to preclinical/clinical quality evaluations—he has successfully supported multiple innovative drug projects in obtaining IND approval.
Organizers
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.
Click here to learn more